Unfractionated Heparin (UFH)

Comprehensive Clinical Guide: Unfractionated Heparin (UFH)

1. Introduction and Overview

Unfractionated Heparin (UFH) remains a cornerstone of anticoagulant therapy in modern clinical practice. Despite the emergence of Low Molecular Weight Heparins (LMWH) and Direct Oral Anticoagulants (DOACs), UFH retains a critical role in hospital-based medicine due to its rapid onset of action, short half-life, and complete reversibility.

As a heterogeneous mixture of glycosaminoglycans, UFH acts as a potent indirect thrombin inhibitor. It is the preferred anticoagulant in patients with significant renal impairment, those requiring urgent surgical intervention, or patients in unstable hemodynamic states where immediate cessation of anticoagulation may be required. This guide serves as a definitive resource for clinicians, pharmacists, and medical staff managing UFH therapy.

2. Mechanism of Action: The Molecular Deep-Dive

The efficacy of UFH is predicated on its interaction with Antithrombin III (ATIII), an endogenous plasma protein that inhibits serine proteases in the coagulation cascade.

• Binding Affinity: UFH contains a specific pentasaccharide sequence with a high affinity for ATIII.
• The Catalytic Effect: Upon binding, UFH induces a conformational change in ATIII, accelerating its rate of neutralization of thrombin (Factor IIa) and Factor Xa by approximately 1,000 to 10,000-fold.
• Thrombin Inhibition: Unlike LMWH, UFH is long enough to form a ternary complex between ATIII and thrombin. This bridging function is required to effectively inhibit thrombin, which is the final effector of the coagulation cascade.
• Factor Xa Inhibition: UFH also inhibits Factor Xa, though its primary clinical impact in therapeutic dosing is the inhibition of thrombin and the subsequent prevention of fibrin clot formation.

3. Pharmacokinetics and Pharmacodynamics

Understanding the PK/PD profile of UFH is essential for safe titration in the clinical setting.

• Administration: Primarily intravenous (IV) for therapeutic anticoagulation; subcutaneous (SC) for prophylactic purposes.
• Onset: Immediate following IV bolus.
• Distribution: Highly protein-bound (to albumin, fibrinogen, and platelet factor 4). This accounts for the unpredictable dose-response relationship among different patients.
• Metabolism: Hepatic metabolism by heparinase and renal excretion.
• Half-life: Dose-dependent. Approximately 60–90 minutes following an IV bolus.

4. Clinical Indications and Usage

UFH is indicated for a wide spectrum of thrombotic and cardiovascular conditions.

Therapeutic Indications:

1. Venous Thromboembolism (VTE): Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
2. Acute Coronary Syndromes (ACS): Management of ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI).
3. Atrial Fibrillation: Used for rapid anticoagulation in patients undergoing cardioversion or those with high thromboembolic risk.
4. Extracorporeal Circuits: Prevention of clotting during hemodialysis, cardiopulmonary bypass (CPB), and ECMO.

Prophylactic Indications:

1. Surgical Prophylaxis: Prevention of VTE in high-risk surgical patients.
2. Medical Prophylaxis: Prevention of venous stasis in bedridden, critically ill patients.

5. Dosage Guidelines

Dosage must be individualized based on weight and monitored via the Activated Partial Thromboplastin Time (aPTT) or Anti-Xa levels.

Standard IV Loading Dose: 80 units/kg bolus.
Standard IV Maintenance Infusion: 18 units/kg/hour.

Note: Always adhere to institutional nomograms.

6. Risks, Side Effects, and Contraindications

Major Risks:

• Hemorrhage: The most common adverse effect. Sites include gastrointestinal, intracranial, and retroperitoneal spaces.
• Heparin-Induced Thrombocytopenia (HIT): An immune-mediated reaction occurring 5–10 days after initiation. It is characterized by a >50% drop in platelet count and paradoxical thrombosis.

Absolute Contraindications:

• Active major bleeding.
• History of HIT (Type II).
• Severe thrombocytopenia.
• Recent neurosurgical or ophthalmic procedures.
• Uncontrolled severe hypertension.

7. Pregnancy and Lactation

• Pregnancy: UFH is the anticoagulant of choice for pregnant patients. It does not cross the placenta due to its large molecular weight and high negative charge.
• Lactation: UFH is not secreted into breast milk. It is considered safe for nursing mothers.

8. Drug Interactions

Clinicians must exercise caution when combining UFH with agents that affect hemostasis:
* Antiplatelet Agents: Aspirin, Clopidogrel, GPIIb/IIIa inhibitors (synergistic bleeding risk).
* NSAIDs: Increased risk of GI mucosal injury and bleeding.
* Thrombolytics: High risk of catastrophic hemorrhage.

9. Overdose Management

In the event of life-threatening hemorrhage:
1. Discontinue infusion immediately.
2. Protamine Sulfate: The specific reversal agent.
* 1 mg of protamine neutralizes approximately 100 units of heparin.
* Administer slowly (max 5 mg/min) to avoid hypotension and anaphylaxis.

10. Frequently Asked Questions (FAQ)

Q1: Why is UFH preferred over LMWH in renal failure?
A: LMWH is primarily cleared by the kidneys. In patients with a CrCl < 30 mL/min, LMWH accumulates, increasing bleeding risk. UFH is cleared by the reticuloendothelial system and is safer in renal failure.

Q2: What is the defining feature of HIT?
A: HIT is an immune reaction where antibodies form against the Heparin-PF4 complex. It causes platelet activation and a sharp decline in platelet counts, paradoxically leading to clots.

Q3: How do I calculate the Protamine dose?
A: If the heparin was given in the last 30 minutes, neutralize 100% of the dose. If 30–60 minutes prior, neutralize 50–75%. If >2 hours, neutralize 25–37.5%.

Q4: Does UFH require routine monitoring?
A: Yes, therapeutic UFH requires frequent aPTT monitoring to ensure the patient is within the therapeutic window.

Q5: Can UFH be used in patients with an epidural catheter?
A: Extreme caution is required. Guidelines suggest waiting 4–6 hours after a dose before catheter removal to prevent spinal hematoma.

Q6: What is the "Heparin Resistance" phenomenon?
A: Some patients require extremely high doses of UFH to reach therapeutic aPTT levels. This is often due to high levels of heparin-binding proteins or ATIII deficiency.

Q7: Is there a benefit to Anti-Xa monitoring over aPTT?
A: Anti-Xa is more specific to the anticoagulant effect of heparin and is less influenced by inflammatory states or factor deficiencies than the aPTT.

Q8: What should I do if a patient develops HIT?
A: Stop all heparin products immediately, including heparin flushes. Initiate a non-heparin anticoagulant like Argatroban or Bivalirudin.

Q9: Does UFH cause osteoporosis?
A: Long-term use (months) of UFH is associated with bone mineral density loss. LMWH is generally considered to have a lower risk in this regard.

Q10: Can UFH be given IM?
A: No. Intramuscular administration of heparin is strictly contraindicated due to the high risk of hematoma formation at the injection site.

11. Conclusion

Unfractionated Heparin remains an indispensable tool in the orthopedic and critical care armamentarium. While its narrow therapeutic index and potential for HIT necessitate diligent monitoring, its unique profile—specifically its rapid reversibility and safety in renal impairment—ensures its continued relevance. Clinicians must maintain a high index of suspicion for adverse reactions and strictly adhere to institution-specific nomograms to optimize patient outcomes.

Disclaimer: This document is for educational purposes only and does not supersede local hospital protocols or the judgment of the attending physician. Always consult the latest clinical guidelines when prescribing high-alert medications.